Literature DB >> 21148504

Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.

Jared M Baeten1, Jairam Lingappa, Ingrid Beck, Lisa M Frenkel, Gregory Pepper, Connie Celum, Anna Wald, Kenneth H Fife, Edwin Were, Nelly Mugo, Jorge Sanchez, Myron Essex, Joseph Makhema, James Kiarie, Carey Farquhar, Lawrence Corey.   

Abstract

Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21148504      PMCID： PMC3024584          DOI： 10.1093/infdis/jiq013

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  14 in total

1.  T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy.

Authors:  Willscott E Naugler; Florence H Yong; Vincent J Carey; Joan A Dragavon; Robert W Coombs; Lisa M Frenkel
Journal:  J Infect Dis       Date:  2002-01-31       Impact factor: 5.226

2.  The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.

Authors:  Moira A McMahon; Janet D Siliciano; Jun Lai; Jun O Liu; James T Stivers; Robert F Siliciano; Rahul M Kohli
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

3.  Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Authors:  C Celum; A Wald; J R Lingappa; A S Magaret; R S Wang; N Mugo; A Mujugira; J M Baeten; J I Mullins; J P Hughes; E A Bukusi; C R Cohen; E Katabira; A Ronald; J Kiarie; C Farquhar; G J Stewart; J Makhema; M Essex; E Were; K H Fife; G de Bruyn; G E Gray; J A McIntyre; R Manongi; S Kapiga; D Coetzee; S Allen; M Inambao; K Kayitenkore; E Karita; W Kanweka; S Delany; H Rees; B Vwalika; W Stevens; M S Campbell; K K Thomas; R W Coombs; R Morrow; W L H Whittington; M J McElrath; L Barnes; R Ridzon; L Corey
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

4.  Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial.

Authors:  Jared M Baeten; R Scott McClelland; Lawrence Corey; Julie Overbaugh; Ludo Lavreys; Barbra A Richardson; Anna Wald; Kishorchandra Mandaliya; Job J Bwayo; Joan K Kreiss
Journal:  J Infect Dis       Date:  2004-04-02       Impact factor: 5.226

5.  Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis.

Authors:  R B Van Dyke; J D Connor; C Wyborny; M Hintz; R E Keeney
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

6.  Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.

Authors:  Jared M Baeten; Lara B Strick; Aldo Lucchetti; William L H Whittington; Jorge Sanchez; Robert W Coombs; Amalia Magaret; Anna Wald; Lawrence Corey; Connie Celum
Journal:  J Infect Dis       Date:  2008-12-15       Impact factor: 5.226

7.  Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.

Authors:  Andrea Lisco; Christophe Vanpouille; Egor P Tchesnokov; Jean-Charles Grivel; Angélique Biancotto; Beda Brichacek; Julie Elliott; Emilie Fromentin; Robin Shattock; Peter Anton; Robert Gorelick; Jan Balzarini; Christopher McGuigan; Marco Derudas; Matthias Götte; Raymond F Schinazi; Leonid Margolis
Journal:  Cell Host Microbe       Date:  2008-09-11       Impact factor: 21.023

8.  Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.

Authors:  Sinéad Delany; Nonkululeko Mlaba; Tim Clayton; Godspower Akpomiemie; Alexio Capovilla; Jerome Legoff; Laurent Belec; Wendy Stevens; Helen Rees; Philippe Mayaud
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

9.  HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.

Authors:  Richard A Zuckerman; Aldo Lucchetti; William L H Whittington; Jorge Sánchez; Robert W Coombs; Amalia Magaret; Anna Wald; Lawrence Corey; Connie Celum
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

10.  Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.

Authors:  Giovanina M Ellis; Madhumita Mahalanabis; Ingrid A Beck; Gregory Pepper; Amy Wright; Shannon Hamilton; Sarah Holte; Willscott E Naugler; Diane M Pawluk; Chung-Chen Li; Lisa M Frenkel
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948
View more
  12 in total

1.  Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.

Authors:  Alison L Drake; Alison C Roxby; Francisca Ongecha-Owuor; James Kiarie; Grace John-Stewart; Anna Wald; Barbra A Richardson; Jane Hitti; Julie Overbaugh; Sandra Emery; Carey Farquhar
Journal:  J Infect Dis       Date:  2011-12-06       Impact factor: 5.226

2.  Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.

Authors:  Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

Review 3.  Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions.

Authors:  Ruanne V Barnabas; Connie Celum
Journal:  Curr HIV Res       Date:  2012-04       Impact factor: 1.581

4.  Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.

Authors:  Steven J Reynolds; Fred Makumbi; Kevin Newell; Noah Kiwanuka; Paschal Ssebbowa; George Mondo; Iga Boaz; Maria J Wawer; Ronald H Gray; David Serwadda; Thomas C Quinn
Journal:  Lancet Infect Dis       Date:  2012-03-19       Impact factor: 25.071

5.  Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.

Authors:  Christophe Vanpouille; Andrea Lisco; Jean-Charles Grivel; Leda C Bassit; Robert C Kauffman; Jorge Sanchez; Raymond F Schinazi; Michael M Lederman; Benigno Rodriguez; Leonid Margolis
Journal:  Clin Infect Dis       Date:  2015-03-03       Impact factor: 9.079

6.  High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.

Authors:  Tara Perti; Misty Saracino; Jared M Baeten; Christine Johnston; Kurt Diem; Negusse Ocbamichael; Meei-Li Huang; Stacy Selke; Amalia Magaret; Lawrence Corey; Anna Wald
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

7.  High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.

Authors:  Kenneth Mugwanya; Jared M Baeten; Nelly R Mugo; Elizabeth Irungu; Kenneth Ngure; Connie Celum
Journal:  J Infect Dis       Date:  2011-10-12       Impact factor: 5.226

8.  Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir.

Authors:  Alison C Roxby; Amy Y Liu; Alison L Drake; James N Kiarie; Barbra Richardson; Barbara L Lohman-Payne; Grace C John-Stewart; Anna Wald; Stephen De Rosa; Carey Farquhar
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-04       Impact factor: 2.205

9.  Time to refocus on HSV interventions for HIV prevention?

Authors:  Clare Tanton; Laith J Abu-Raddad; Helen A Weiss
Journal:  J Infect Dis       Date:  2011-10-12       Impact factor: 5.226

10.  Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters.

Authors:  Jairam R Lingappa; Katherine K Thomas; James P Hughes; Jared M Baeten; Anna Wald; Carey Farquhar; Guy de Bruyn; Kenneth H Fife; Mary S Campbell; Saidi Kapiga; James I Mullins; Connie Celum
Journal:  AIDS Res Hum Retroviruses       Date:  2013-01       Impact factor: 2.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.